Adult Neurogenesis Therapeutics represents an emerging investment area focused on stimulating the brain's natural ability to generate new [neurons](/entities/neurons) to treat neurodegenerative diseases. This investment landscape analyzes funding trends, key companies, clinical trials, and opportunities in this field. [@adult2023]
Adult neurogenesis - the production of new neurons in the adult brain - occurs primarily in two regions: the subventricular zone (SVZ) lining the ventricles and the subgranular zone (SGZ) of the dentate gyrus in the [hippocampus](/brain-regions/hippocampus). This capacity diminishes with age and is impaired in neurodegenerative diseases, making restoration of neurogenesis a compelling therapeutic approach.
Biological Rationale
Why Neurogenesis Matters
Cognitive function: New neurons integrate into hippocampal circuits supporting memory
Disease modification: Replace lost neurons rather than just symptomatic treatment
Combination potential: Works with other approaches (anti-amyloid, neuroprotection)
Challenges
Survival: Most new neurons die within weeks of birth
Integration: Functional circuit integration is challenging
Delivery: Getting cells or drugs to appropriate brain regions
Timing: When in disease progression is intervention most effective?
Investment Trends
Funding Overview
The adult neurogenesis therapeutics field has attracted increasing investment interest from venture capital and pharmaceutical companies: [@neurogenesis2024]
Venture Capital: Active investment in stem cell therapy companies and neural regeneration startups
Pharma Partnerships: Major pharmaceutical companies partnering with academic labs and biotech
Government Funding: NIH and EU grants supporting neural stem cell research
Market Size
Growing from $500M (2020) to projected $2B+ by 2030
Large-scale manufacturing: Scalable stem cell production
Delivery technologies: Targeted brain region injection
Combination approaches: Neurogenesis + other mechanisms
Biomarkers: Neural progenitor cell markers in humans
Patient selection: Genetic/disease stage predictors of response
Investment Opportunities
Autologous iPSC-derived neuron therapy
Small molecule neurogenesis enhancers
Biomarker development for patient selection
Brain-penetrant neurotrophic factors
Conclusion
Adult neurogenesis therapeutics represent a long-term bet on neural regeneration. While no late-stage programs exist yet, the fundamental biology provides a compelling rationale. Key to success will be:
Demonstrating functional integration of new neurons